D. Boral Capital Reiterates Buy Rating for Cytosorbents (NASDAQ:CTSO)

Cytosorbents (NASDAQ:CTSO)‘s stock had its “buy” rating reaffirmed by equities research analysts at D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They presently have a $10.00 price objective on the medical research company’s stock.

Other equities research analysts have also issued research reports about the company. HC Wainwright lowered their price objective on Cytosorbents from $1.00 to $0.75 and set a “neutral” rating on the stock in a research report on Friday, November 14th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cytosorbents in a research note on Tuesday, October 14th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $5.38.

Cytosorbents Price Performance

Shares of CTSO opened at $0.73 on Monday. The business’s 50-day moving average is $0.70 and its two-hundred day moving average is $0.87. The company has a market capitalization of $45.84 million, a P/E ratio of -4.06 and a beta of 1.32. The company has a debt-to-equity ratio of 1.61, a quick ratio of 1.71 and a current ratio of 2.11. Cytosorbents has a fifty-two week low of $0.60 and a fifty-two week high of $1.61.

Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings data on Thursday, November 13th. The medical research company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.02. The business had revenue of $9.49 million during the quarter, compared to analysts’ expectations of $10.02 million. Cytosorbents had a negative return on equity of 101.14% and a negative net margin of 27.77%. Research analysts predict that Cytosorbents will post -0.3 earnings per share for the current year.

Institutional Investors Weigh In On Cytosorbents

Several large investors have recently bought and sold shares of CTSO. Avenir Corp lifted its position in shares of Cytosorbents by 0.3% in the second quarter. Avenir Corp now owns 5,058,537 shares of the medical research company’s stock valued at $6,475,000 after acquiring an additional 13,619 shares in the last quarter. Vanguard Group Inc. raised its stake in Cytosorbents by 3.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock valued at $2,059,000 after purchasing an additional 79,535 shares during the last quarter. CM Management LLC lifted its holdings in Cytosorbents by 3.1% in the 3rd quarter. CM Management LLC now owns 1,288,128 shares of the medical research company’s stock valued at $1,203,000 after purchasing an additional 38,128 shares in the last quarter. CIBC Bancorp USA Inc. acquired a new stake in Cytosorbents during the 3rd quarter worth $161,000. Finally, GSA Capital Partners LLP acquired a new stake in Cytosorbents during the 3rd quarter worth $105,000. 32.87% of the stock is currently owned by hedge funds and other institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.